Activist investor Starboard Value LP plans to vote against Bristol-Myers Squibb ...
- Activist investor Starboard Value LP plans to vote against Bristol-Myers Squibb Co’s proposed $74 billion takeover of biotech Celgene Corp and urged other shareholders to join it in voting down the “poorly conceived and ill-advised” deal.
The shareholder opposition imperils what would be the largest pharmaceutical acquisition of all time. Starboard, one of the industry’s most prominent and successful activist investors, also said that it will sue Bristol for documents in Delaware court to gain a better understand how management decided to make the offer for Celgene.
Bristol-Myers said Starboard informed the company it had bought roughly one million of its common shares. That is equivalent to a roughly $50 million stake, a sliver of the company’s $84 billion market value.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Activist investor Starboard Value says it will oppose Bristol-Myers' $74 billion deal for CelgeneActivist investor Starboard Value said that it intends to use its stake in Bristol-Myers Squibb to oppose the drug-maker’s acquisition of Celgene.
Weiterlesen »
Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Weiterlesen »
Starboard Details Opposition to Bristol-Myers Deal for CelgeneActivist investor Starboard Value detailed its opposition to Bristol-Myers Squibb’s proposed acquisition of Celgene, describing the proposed takeover as poorly conceived and ill advised.
Weiterlesen »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Weiterlesen »
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Weiterlesen »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Weiterlesen »
Bristol-Myers $74 bln deal needs surgeryBig shareholder Wellington Management and activist Starboard Value have both come out against the pharma firm’s deal for Celgene. The market also isn’t pricing in the acquisition happening as Bristol-Myers envisaged. It doesn’t help that the buyer was already overpaying.
Weiterlesen »
Foreigners Snap Up Smaller China Stocks Ahead of MSCI MoveForeign investors have piled into shares of technology-focused companies and other smaller stocks in China, encouraged by their likely inclusion in MSCI’s global benchmarks.
Weiterlesen »
US Treasury yields move higher ahead of another Powell speechU.S. government debt prices were lower on Wednesday morning, as investors awaited another speech from Federal Reserve Chairman Jerome Powell.
Weiterlesen »